Subscribe to our Newsletters !!
Like never seen before, coral reefs across the
Lab vials are some of the smallest containers in a
Dr. Mohammed Enayat’s recent testimony on his ag
It is with utmost pride that Microbioz India annou
The world of pharmaceuticals encompasses a broad s
Since it’s an ingredient in so many foods, you h
In our cover story, we shine a spotlight on “ The Magazine
The Hyderabad-based firm has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, Dr Reddy”s Laboratories said in a statement.
In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a permit to sell volume-limited amounts of generic lenalidomide capsules in america starting on a confidential date after March 2022 subject to regulatory approval, it added.
The agreed-upon proportions are confidential, Dr Reddy”s said.
The drug maker is already licensed to sell generic lenalidomide capsules in the US without volume limitation starting on January 31, 2026, Dr Reddy”s said.
“We are satisfied with the settlement agreement, and look forward to bringing a generic version of lenalidomide to market shortly subject to regulatory approval for the benefit of patients,” Dr Reddy”s Laboratories North America Generics CEO Marc Kikuchi said.
Revlimid, a trademark of Celgene, is used in the treatment of multiple myeloma and myelodysplastic syndromes. PTI MSS RVK
